Literature DB >> 2869952

Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients.

J R M'Buyamba-Kabangu, B Lepira, R Fagard, P Lijnen, M Ditu, K A Tshiani, A Amery.   

Abstract

The short-term efficacy of nitrendipine (N) as a first stage antihypertensive drug in black patients has been assessed and compared with acebutolol (A) in a double-blind study. Forty patients were randomized and after a 4 week run-in period on placebo, the active treatment was administered for 6 weeks starting with 20 mg N or 200 mg A once daily. The dose was increased up to 60 mg N or 600 mg A as needed. Nitrendipine appeared to be more efficient than acebutolol in reducing blood pressure and the N-induced fall in blood pressure was achieved after 2 weeks. After 2 and 6 weeks on N, the recumbent blood pressure was decreased by 13% and 12% for the systolic and by 14% and 11% for the diastolic pressure. The concurrent decreases in the A group averaged 4% and 5% for the systolic and 5% and 10% for the diastolic pressure after 2 and 6 weeks. Pulse rate and plasma renin activity in the N group were slightly increased and body weight was decreased at the end of the active treatment period.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869952     DOI: 10.1007/bf00635887

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Suppressed plasma renin activity in hypertension.

Authors:  B J Channick; E V Adlin; A D Marks
Journal:  Arch Intern Med       Date:  1969-02

2.  Essential hypertension: renin and aldosterone, heart attack and stroke.

Authors:  H R Brunner; J H Laragh; L Baer; M A Newton; F T Goodwin; L R Krakoff; R H Bard; F R Bühler
Journal:  N Engl J Med       Date:  1972-03-02       Impact factor: 91.245

3.  Ineffectiveness of propranolol in hypertensive Jamaicans.

Authors:  G S Humphreys; D G Delvin
Journal:  Br Med J       Date:  1968-06-08

4.  Metabolic studies on hypertensive patients with suppressed plasma renin activity not due to hyperaldosternosm.

Authors:  O M Helmer; W E Judson
Journal:  Circulation       Date:  1968-11       Impact factor: 29.690

5.  Intracellular concentration and transmembrane fluxes of sodium and potassium in erythrocytes of normal male subjects. Effect of family history of hypertension and race.

Authors:  P Lijnen; R Fagard; D Groeseneken; J R M'Buyamba-Kabangu; J Staessen; W Lissens; A Amery
Journal:  Neth J Med       Date:  1984       Impact factor: 1.422

6.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

7.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

8.  Trial of atenolol and chlorthalidone for hypertension in black South Africans.

Authors:  Y K Seedat
Journal:  Br Med J       Date:  1980-11-08

9.  Experience with nitrendipine--a new calcium antagonist--in hypertension.

Authors:  L Andrén; L Hansson; L Orö; T Ryman
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

10.  Heterogeneity of systemic hemodynamic response to a new calcium entry blocker, nitrendipine.

Authors:  F M Fouad; M Aboul-Khair; R C Tarazi
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

View more
  4 in total

Review 1.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

Review 2.  Choosing the correct drug for the individual hypertensive patient.

Authors:  L H Opie
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 3.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 4.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.